-
Epizyme's Tazemetostat Drug For Epithelioid Sarcoma Gets Accelerated FDA Approval
Friday, January 24, 2020 - 6:52am | 313Biopharmaceutical company Epizyme Inc. (NASDAQ: EPZM) on Thursday said that its tazemetostat drug for the treatment of patients with epithelioid sarcoma had been approved by the Food and Drug Administration. What Happened The TAZVERIK drug has been approved, particularly for the...